Q1 Earnings Forecast for FHTX Issued By B. Riley

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Research analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Foghorn Therapeutics in a report issued on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.34) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.09) EPS and FY2027 earnings at ($1.34) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.13. The firm had revenue of $2.86 million for the quarter, compared to analyst estimates of $8.56 million.

Other analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a report on Friday, March 7th. Jefferies Financial Group dropped their target price on shares of Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Monday, December 16th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Foghorn Therapeutics has an average rating of “Buy” and an average price target of $13.17.

Foghorn Therapeutics Price Performance

Shares of NASDAQ FHTX opened at $4.44 on Monday. The company has a 50 day simple moving average of $4.68 and a 200-day simple moving average of $6.54. The company has a market capitalization of $246.92 million, a P/E ratio of -2.31 and a beta of 3.13. Foghorn Therapeutics has a 1 year low of $3.86 and a 1 year high of $10.25.

Hedge Funds Weigh In On Foghorn Therapeutics

Several institutional investors have recently modified their holdings of the business. Deerfield Management Company L.P. Series C lifted its position in shares of Foghorn Therapeutics by 7.5% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,255,514 shares of the company’s stock worth $15,366,000 after purchasing an additional 227,628 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Foghorn Therapeutics during the 4th quarter worth $9,579,000. Geode Capital Management LLC lifted its position in shares of Foghorn Therapeutics by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 682,863 shares of the company’s stock worth $3,224,000 after purchasing an additional 5,477 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Foghorn Therapeutics by 58.8% during the 4th quarter. Point72 Asset Management L.P. now owns 634,761 shares of the company’s stock worth $2,996,000 after purchasing an additional 235,059 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Foghorn Therapeutics by 4.9% during the 3rd quarter. State Street Corp now owns 505,945 shares of the company’s stock worth $4,710,000 after purchasing an additional 23,630 shares during the last quarter. Institutional investors and hedge funds own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.